Johandesilva
30 Apr 2018
Re: SP movement tall shipI too am well experienced at this VAL is going to my last throw of the AIM dice as I reach a key milestone in my life. Great late report trades brings some confidence but as always the negatives are that this is YA backed stocked meaning no other bogger sees any value as clearly shown in the share register. I hope will change with an RNS tomorrow morning.Good luck
Tired and Confused
30 Apr 2018
Re: SP movement One of my more indulgent investments and lucky to get out of the majority on a small profit (not realised as they are held in 'free shares') after years of averaging down.I think VAL have a good chance of finding a partner but as for the dream of a multibagger well, that's water under the bridge, IMHO.Dilution has finished any hopes of a major re-rating and sadly this has been pretty much confirmed by the greedy BOD who have awarded themselves undemanding options (4p) and continue to pay themselves handsomely, disproportionately IMHO given the dreadful financial performance they have delivered for shareholders.Still I'm in to see the last card turned on this one.
tall ship
30 Apr 2018
Re: SP movement Johandesilva,Had a little chuckle at your post, yes I have been in this game for a few years, made good money and threw good money after bad, but after all these years a little bit wiser but not much richer.May I qualify my comment of ' all in on this one ' I should have said I have may maximum stake money put in this share after buying at 3.5 and then averaging down until recent rise.I need this one to balance the books after a £3k loss on IMM Once this gets past 4.5, there is something positive in the pipeline IMHO
Johandesilva
30 Apr 2018
Re: SP movement tall ship,Your member since 2000 and are all in on this one! Good luck but I suppose your experienced enough not to need it!
tall ship
30 Apr 2018
SP movement SP now £4.20 to buy, from £3.75 open, I believe the joint venture will be announced before the AGM, that will give them something to shout about at the AGM, with lots of back slapping etc, imho. So, I'm ' all in on this one ' get in before the fuse is lit is my advice, for what it is worth. good luck to all holder
Johandesilva
27 Apr 2018
Re: RNS I am presuming 0.3m cash required a month so there is less than a couple of months worth of cash in the bank? Only two outcomes possible. Dilution or deal.
fredd1eboy
27 Apr 2018
Re: RNS A little bit more patience required. Still 7 trading days of "hopefully" continued share price recovery available before agm.....we have plenty of scopeto regain a decent sp prior to an rns on jv. Enjoy the time!
clockwurktangerine
26 Apr 2018
Re: RNS Good post!Hence my comment private equity and give will back ucl.ac.uk projects not aim listed ValToo many salaried ackerdemics fancy having bod salaries via sharesUcl are also very prestigious researchers.Val if such a good product where is the private equity funding?Just ya!!!And will they ever get bought out or jv!
Tired and Confused
26 Apr 2018
Re: RNS I certainly agree that companies like VAL shouldn't IPO until they are investable. The result of going public too early is inevitably, you're going to mislead investors because there are virtually never enough funds from the IPO to see the business through to commercial viability, let's be generous, 99% need more and then more funding but the truth is 100%!This is never reflected in the initial IPO prospectus. It never says we are going to take your money and then give you some shares and after a matter of months issue more and more share (by the way we won't give you the chance to take part, sucker) until we dilute the shares you originally bought until they are worth pretty much nothing. And, we will raise funds from lenders of last resort on top, rig the market with carefully timed 'news' so the lender of last resort can flog the shares they have taken for cash and get out. Then we will go back to them again and again and do the same thing. Eventually, we will proudly announce after years of cash-burn that we have developed our business, at the expense of those seed investors to the point where we believe we truly have an investable proposition. Now this is all hypothetical but if the cap fits VAL, they should blo0dy wel wear it!AIMHO and DYOR
Johandesilva
26 Apr 2018
Re: RNS Clockwork - sorry had you on ignore from your days on the other YA related stock forum and was only visible when I was logged out. Your strategy is a good one and you know I understand you hence the reply. But you remain on my ignore and hope to prove you wrong in the longer run
clockwurktangerine
25 Apr 2018
Re: RNS The point is a start up should not even consider an IPO till it had made good progress, and is attractive to investors.Val just came to market with great hype, which is when you should have soldIt went from 78p down to 0.9pMost investors will never break even.And talks of s buyout jv will never happen, big pharmas won't offer much if they were interested...
Johandesilva
25 Apr 2018
Re: RNS Couple of points IMHO:* Staff remuneration has to be ahead of share holder value. The other way round will destroy share holder value in the long run.* Without YA companies like VAL, XTR etc... would all have most likely gone into liquidation as there are no institutions here as share holders who think this is is worth anything. We owe YA a thanks even if does feel like we are being bent over!Good to see somebody with deeper pockets than us picking up stock. If a new institution is reported in a RNS as buying this could then step up in price, but equally if PI's are left to hold this baby then you know what babies produce! Clearly though we do also need a deal this year as the number of products and stages all demand more and more money.
clockwurktangerine
25 Apr 2018
Re: RNS I agreeThe gov would award the likes of ucl.ac.uk funds not sim listed.Icl employs researchers on ackerdemic salaries, Val lot we're probs prev ackerdemics who fancied bodsalaries.Ucl would only have an IPO only if they had achieved a lot of progress!And uni incubator companies attract private equityVal attracts YA! LolNo one other then ya have invested in Val, hence all the dilution!!!Thanks
Tired and Confused
25 Apr 2018
RNS I posted this on the 13th February 2018The total number of warrants held by senior management is 5% of the total share capital.Of these 83% were issued as announced in the RNS dated the 9th Feb 2018. These were issued at 4p for conversion at any time up to 7th Feb 2028. This means that my original post was incorrect. It should have said that they have awarded themselves 4% of the share capital with a further 1% of the share capital already held by them in 'more demanding' warrants which can be converted at between 43.125p and 125p 
Now forgive me for saying this but it seems to me that the management have decided that due to massive dilution over the years they have no faith in the share price reaching 43.125p let alone 125p so they have issue a bucket full of new warrants which can be converted and sold? for a few pence profit on a spike in the current share price trading range. Or am I being too cynical? ENDGreat RNS today but and it's a really big BUT; do the management really expect us to believe that the share price is about to break out when they have awarded themselves such large numbers of ludicrously undemanding options?They pay themselves wages which are at a significant premium to those researching outside PLC's and place additional burdens on PI's and other investors with these 'snout in the trough' options.Yes VAL has potential but they are making pretty sure they deliver for themselves first and foremost regardless whether they ultimately deliver for investors.Fund raising and dilution can only be days away now IMHO and it always comes after an RNS!!!!AIMHO and DYOR
dickie3times
25 Apr 2018
EU Patent Grant Best news for VAL for months.....next move will bed a farm-in deal by one of a multitude of majors. Best case scenario could well be more than one pharma may announce interest. BUT, imo these compounds are so good at 'early stage development', that VAL may be approached very very soon. So good in fact, shrewd pharmas may be seeing early value, NOW, rather than risk losing out by waiting for full FDA approval.The time for deals with Valirx is now, with these WW patents now lined up. Finance may soon NOT be an issue, someone with deep pockets snap us up, or at least a JV partnership?[link] EPO patent application covers the molecule and use of compounds in pharmaceutically acceptable products and it applies in the following territories: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR. The patent coverage also includes a wide variety of derivatives, modifications and analogues of the compounds and their mode of action. Furthermore, the protection sought includes therapeutic formulations with associated delivery systems. The grant of this EU patent for VAL201 represents another major milestone in the Company's commercial strategy, since ValiRx now has substantial patent protection across the globe. With the Company now having patent protection in all major markets, it is well positioned to benefit from the pharmaceutical industry's increasing search for novel proprietary therapies in the oncology arena.
